US authorises increased production of Takeda’s ADHD drug to address shortages
The US Drug Enforcement Administration has increased the production limit for Takeda Pharmaceuticals’ ADHD drug Vyvanse and its generics have increased in price by about 24 per cent to address the ongoing shortage of the drug in the United States.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO